Last $13.13 USD
Change Today +0.03 / 0.23%
Volume 562.8K
NXTM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

nxstage medical inc (NXTM) Snapshot

Open
$13.18
Previous Close
$13.10
Day High
$13.29
Day Low
$12.97
52 Week High
08/7/14 - $15.50
52 Week Low
11/19/13 - $8.77
Market Cap
811.8M
Average Volume 10 Days
282.7K
EPS TTM
$-0.37
Shares Outstanding
61.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NXSTAGE MEDICAL INC (NXTM)

Related News

No related news articles were found.

nxstage medical inc (NXTM) Related Businessweek News

No Related Businessweek News Found

nxstage medical inc (NXTM) Details

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Its primary product is the NxStage System One, a portable hemodialysis system used for the treatment of acute and chronic kidney failure, and fluid overload. The company operates in two segments, System One and In-Center. The System One segment sells and rents the NxStage System One and PureFlow SL dialysate preparation equipment. This segment also sells extracorporeal disposable products, which are primarily used for in-center dialysis treatments for patients with end-stage renal disease (ESRD) in the home and critical care markets. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers; and needles for apheresis. NxStage Medical, Inc. markets its products through direct sales force and distributors to hospitals and dialysis centers in the United States and internationally. The company, formerly known as QB Medical, Inc., was founded in 1998 and is headquartered in Lawrence, Massachusetts.

3,200 Employees
Last Reported Date: 03/3/14
Founded in 1998

nxstage medical inc (NXTM) Top Compensated Officers

Founder Chief Executive Officer and Director
Total Annual Compensation: $437.1K
President
Total Annual Compensation: $308.4K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $136.3K
President of Nxstage Kidney Care, Inc
Total Annual Compensation: $295.1K
Senior Vice President of Quality Assurance, R...
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2013.

nxstage medical inc (NXTM) Key Developments

NxStage(R) Medical, Inc. Announces FDA Clearance of Single Needle Technology

NxStage(R) Medical, Inc. announced its single needle technology, OneSite(TM), has received FDA clearance. The OneSite employs a unique dual lumen needle design offered in both a sharp version with MasterGuard(R) and a buttonhole version with SteriPick(R) allowing the dialysis patient to have only one needle inserted per dialysis treatment instead of two. The combination of single site and buttonhole access is designed to provide patient comfort during needle insertion and dialysis treatment, as well as preservation of the patient's vascular access. The dual lumen design also enhances patient safety during treatment by having the machine alarm and shutdown upon access dislodgement, reducing the risk of undetected Venous Needle Dislodgement (VND) in the use of a two needle treatment. The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs - at home or on vacation and at a medically appropriate treatment frequency.

Nxstage Medical Appoints Allan Collins as Senior Medical Advisor and Head of Company's Medical Advisory Board

Nxstage Medical, Inc. has appointed Allan Collins as senior medical advisor and head of company's medical advisory board. Dr. Collins is a Professor of Medicine at the University of Minnesota. He is the Director of the Chronic Research Disease Group. Dr. Collins has served as a member of the NxStage Scientific Advisory Board for the last 4 years.

Nxstage Medical, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Third Quarter and Full-Year 2014

NxStage Medical, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenues of $74,083,000 compared to $65,462,000 a year ago. Loss from operations was $6,651,000 compared to $4,271,000 a year ago. Net loss before income taxes was $6,863,000 compared to $4,431,000 a year ago. Net loss attributable to stockholders of the company was $7,113,000 or $0.12 basic and diluted per share compared to $3,405,000 or $0.06 basic and diluted per share a year ago. The increase in revenue was driven by strong adoption of the NxStage(R) System One(TM) hemodialysis machine within the Home, both within US and international markets, and the Critical Care market. For the six months, the company reported revenues of $146,304,000 compared to $127,106,000 a year ago. Loss from operations was $11,440,000 compared to $8,807,000 a year ago. Net loss before income taxes was $11,827,000 compared to $9,293,000 a year ago. Net loss attributable to stockholders of the company was $12,388,000 or $0.20 basic and diluted per share compared to $8,399,000 or $0.14 basic and diluted per share a year ago. Net cash used in operating activities was $14,213,000 against $9,737,000 a year ago. The company now expects full-year revenue for 2014 to be between $290 and $293 million, versus its previous guidance of $283 to $288 million. The company's full-year net loss guidance remains unchanged at $23 to $27 million. For the third quarter of 2014, the company expects revenue to be in a range of $71.0 and $72.5 million, and a net loss in the range of $7.5 to $8.5 million. The company expects a sequential decrease in cash spend in the third quarter. Cash spend on NxStage Kidney Care was flat with first quarter at $5 million, consistent with overall plans.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NXTM:US $13.13 USD +0.03

NXTM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $71.77 USD -0.11
Fresenius Medical Care AG & Co KGaA €54.89 EUR +0.86
JMS Co Ltd ¥297.00 JPY -2.00
Nipro Corp ¥911.00 JPY -6.00
View Industry Companies
 

Industry Analysis

NXTM

Industry Average

Valuation NXTM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.8x
Price/Book 4.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NXSTAGE MEDICAL INC, please visit www.nxstage.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.